Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is giant cell tumor of bone?
Giant cell tumor of bone (GCTB) is named for the large, many-nucleus cells seen under the microscope. It typically appears in young adults at the end of a long bone right next to a joint — most often the knee, wrist, or shoulder. It is classified as benign because it rarely spreads, yet it behaves aggressively in place, destroying bone and sometimes returning after treatment. A small fraction can spread to the lungs (usually slow-growing) or, very rarely, turn malignant. The tumor is driven by overactive bone-dissolving cells (osteoclasts) recruited by a signal called RANKL — the target of modern drug therapy.
The main types
Doctors group giant cell tumor of bone by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| Conventional (benign) GCTB | The usual form — locally destructive but does not spread; cured in most people by surgery. |
| GCTB with lung deposits | Rarely, benign-looking tumor cells settle in the lungs; these often grow very slowly and can even regress. |
| Malignant GCTB | A rare, truly cancerous version — either present at diagnosis or developing later, sometimes after radiation. |
Staging, in plain terms
GCTB is not staged with the usual cancer TNM system. Doctors describe it by how much bone it has destroyed on x-ray and MRI using the Campanacci grades, plus whether it has broken through the bone's outer shell.
| Campanacci grade (radiographic), not TNM | What it generally means |
|---|---|
| Grade 1 (quiet) | Well-contained inside the bone with an intact rim; the least aggressive appearance. |
| Grade 2 (active) | The bone shell is thinned and expanded but still holding; the most common presentation. |
| Grade 3 (aggressive) | The tumor has broken through the bone into surrounding soft tissue. |
| Metastatic (lung) | Benign-appearing tumor found in the lungs — uncommon, usually indolent, and watched or treated with denosumab. |
The standard of care
Giant Cell Tumor of Bone is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Surgery — extended curettage
The tumor is scooped out and the cavity treated (with a high-speed burr, and agents like phenol, cement, or liquid nitrogen) to kill leftover cells while saving the joint.
Wider resection for large or recurrent tumors
When too much bone is destroyed, the segment is removed and rebuilt with a graft or joint replacement.
Denosumab for unresectable disease
A RANKL-blocking antibody that quiets the bone-dissolving cells; it can shrink and harden tumors of the spine, pelvis, or skull that surgery can't safely remove, sometimes making later surgery possible.
How radiation treatment works
Radiation damages the DNA of dividing tumor cells so they can no longer multiply, and the tumor gradually stops growing and hardens. For giant cell tumor of bone, radiation is used cautiously and only when surgery and denosumab are not options, because irradiating a benign tumor carries a small long-term risk of malignant change. When it is needed, image-guided, tightly shaped radiation keeps the dose on the tumor and limits exposure to healthy bone. Treatment is painless and given in short daily sessions.
The main ways radiation is delivered for giant cell tumor of bone:
Denosumab (targeted antibody)
Blocks RANKL, the signal that recruits bone-destroying osteoclasts, so the tumor stops eroding bone and often forms a firm shell. Used for spine/sacrum/pelvis tumors and to down-size before surgery.
Radiation therapy (selective, lower priority)
Reserved for tumors that can't be removed and aren't controlled by denosumab — such as some spinal or sacral lesions — because radiation carries a small risk of turning the tumor malignant. Modern conformal techniques lower that risk.
Embolization
Blocking the tumor's blood supply through a catheter can control bleeding and shrink large pelvic or spinal tumors before surgery.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
Denosumab in unresectable GCTB: Studies of inoperable or locally advanced tumors show denosumab produces durable tumor response, pain relief, and surgical down-staging; it is now the treatment of choice when surgery would cause major harm.[1]
Ann. Oncology (PubMed 28101196)
Stopping denosumab — does it regrow?: 2025 analysis found many unresectable tumors can progress after the drug is stopped, supporting ongoing or maintenance dosing strategies and close monitoring.[2]
Cancer Reports (Wiley, 2025)
Denosumab regimens meta-analysis: Systematic review with meta-analysis compared dosing schedules and confirmed high response rates while highlighting the lack of a standardized treatment length.[3]
World J. Orthopedics (2025)
Common questions
Is this cancer? It is classified as benign — it almost never spreads — but it is locally aggressive and destroys bone, so it must be treated thoroughly. A small minority can spread to the lungs or rarely become malignant, which is why follow-up matters.
Will I lose my joint? Usually not. Most tumors are removed by extended curettage that preserves the joint. Only when too much bone is destroyed is the segment replaced with a graft or prosthesis.
Why is radiation used so carefully here? Because GCTB is benign and often affects young people, irradiating it carries a small long-term risk of turning it cancerous. So radiation is saved for tumors that can't be removed or controlled with denosumab, using precise modern techniques.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.